IP Library › Granted Patent US 12,674,059
Granted Patent B2
US 12,674,059 · App. 18/120,554 · Granted Jul 7, 2026

Violet excitable tandem dyes, and methods for making and using the same

Inventors: Glenn Bartholomew (Escondido, CA); David Michel Moureau (San Diego, CA); Itzel Vaca (San Diego, CA)
Assignee: Becton, Dickinson and Company
C09B69/109G01N33/54326G01N33/563G01N33/582G01N33/68G01N2446/90
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,674,059
App. No.
18/120,554
Granted
Jul 7, 2026
Kind
B2
Abstract

Violet excitable tandem dyes are provided. Tandem dyes of embodiments of the invention include: a non-conjugated polymeric backbone; one or more violet excitable donor fluorophores linked to the non-conjugated polymeric backbone; and one or more acceptor fluorophores linked to the non-conjugated polymeric backbone; where the donor and acceptor fluorophores are in energy transfer relationship. Also provided are methods of making and using the tandem dyes, as well as kits that include the dyes and find use in embodiments of the methods.

Claims (23)

1 . A tandem dye comprising:

a non-conjugated polymeric backbone;

one or more violet excitable donor fluorophores selected to have an absorption maximum ranging from 375 to 425 nm linked to the non-conjugated polymeric backbone; and

one or more acceptor fluorophores linked to the non-conjugated polymeric backbone,

wherein the donor and acceptor fluorophores are in energy transfer relationship.

2 . The tandem dye according to claim 1 , wherein the one or more violet excitable donor fluorophores are selected from the group consisting of coumarin fluorophores, pyrene fluorophores and triphenyl fluorophores.

3 . The tandem dye according to claim 2 , wherein the one or more violet excitable donor fluorophores are coumarin fluorophores.

4 . The tandem dye according to claim 1 , wherein the one or more violet excitable donor fluorophores are bonded to a water-solubilizing group.

5 . The tandem dye according to claim 4 , wherein the water-solubilizing group comprises a non-ionic water solubilizing group.

6 . The tandem dye according to claim 5 , wherein the non-ionic water-solubilizing group comprises a polyalkylene glycol.

7 . The tandem dye according to claim 6 , wherein the polyalkylene glycol comprises a polyethylene glycol.

8 . The tandem dye according to claim 1 , wherein the one or more acceptor fluorophores has an emission maximum ranging from 500 to 875 nm.

9 . The tandem dye according to claim 1 , wherein the one or more acceptor fluorophores is selected from the group consisting of coumarin dyes, cyanine dyes, rhodamine dyes, xanthene dyes, polymethines, dipyrromethene borondifluorides, napthalimides, thiazine dyes, and acridine dyes.

10 . The tandem dye according to claim 1 , wherein the number of donor fluorophores exceeds the number of acceptor fluorophores.

11 . The tandem dye according to claim 10 , wherein the number of donor fluorophores ranges from 2 to 20.

12 . The tandem dye according to claim 1 , wherein the dye comprise a single acceptor fluorophore.

13 . The tandem dye according to claim 1 , wherein the tandem dye is linked to a biomolecule.

14 . The tandem dye according to claim 13 , wherein the biomolecule is selected from the group consisting of carbohydrates, lipids, nucleic acids, and proteins.

15 . The tandem dye according to claim 14 , wherein the biomolecule is a binding member.

16 . The tandem dye according to claim 15 , wherein the binding member is an antibody or binding fragment or derivative thereof.

17 . The tandem dye according to claim 1 , wherein the tandem dye is linked to a chemo-selective group.

18 . The tandem dye according to claim 1 , wherein the non-conjugated polymeric backbone comprises a peptide.

19 . The tandem dye according to claim 18 , wherein the peptide comprises from 5 to 100 amino acid residues.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2023
From: BARTHOLOMEW, GLENN P.; MOUREAU, DAVID MICHEL; VACA, ITZEL PATRICIA
To: BECTON, DICKINSON AND COMPANY
Reel/Frame 063925/0577 →
Continuity (2)
Provisional Application 63322120 · Mar 21, 2022
Related Publication 20230295440A1 · Sep 21, 2023
References Cited (66)
US 3989381A · Fulwylet · 1976 [cited by applicant]
US D339194S · Telang · 1993 [cited by applicant]
US 5574232A · Davidson et al. · 1996 [cited by applicant]
US 5641457A · Vardanega et al. · 1997 [cited by applicant]
US 6079836A · Burr et al. · 2000 [cited by applicant]
US 6372506B1 · Norton · 2002 [cited by applicant]
US 6881580B2 · Hall et al. · 2005 [cited by applicant]
US 7153475B2 · Hill et al. · 2006 [cited by applicant]
US D676567S · Van Den Engh · 2013 [cited by applicant]
US 8455258B2 · Quake et al. · 2013 [cited by applicant]
US 8727132B2 · Miltenyi et al. · 2014 [cited by applicant]
US 8795500B2 · Shinoda · 2014 [cited by applicant]
US D715925S · Suzuki · 2014 [cited by applicant]
US D717438S · Lin · 2014 [cited by applicant]
US 9592483B2 · Fox et al. · 2017 [cited by applicant]
US D802150S · Lund · 2017 [cited by applicant]
US 10221844B2 · Lofstrom et al. · 2019 [cited by applicant]
US 10508990B2 · Fox et al. · 2019 [cited by applicant]
US 10914671B2 · Norton et al. · 2021 [cited by applicant]
US 20040025602A1 · Norton · 2004 [cited by applicant]
US 20040062685A1 · Norton · 2004 [cited by applicant]
US 20040142463A1 · Walker et al. · 2004 [cited by applicant]
US 20050011582A1 · Haug · 2005 [cited by applicant]
US 20060118167A1 · Neas et al. · 2006 [cited by applicant]
US 20110020855A1 · Shinoda et al. · 2011 [cited by applicant]
US 20110024615A1 · Tanner et al. · 2011 [cited by applicant]
US 20110137018A1 · Chabg-Yen et al. · 2011 [cited by applicant]
US 20110217723A1 · Durack · 2011 [cited by applicant]
US 20110259749A1 · Kanda · 2011 [cited by applicant]
US 20110271746A1 · Shinoda · 2011 [cited by applicant]
US 20110284378A1 · Shinoda · 2011 [cited by applicant]
US 20120164718A1 · Bishop et al. · 2012 [cited by applicant]
US 20120202237A1 · Sedoglavich et al. · 2012 [cited by applicant]
US 20120276621A1 · Van Den Engh · 2012 [cited by applicant]
US 20130330739A1 · Yu · 2013 [cited by applicant]
US 20140078502A1 · Buchanan et al. · 2014 [cited by applicant]
US 20140120570A1 · Yu et al. · 2014 [cited by applicant]
US 20140170697A1 · Sharpe et al. · 2014 [cited by applicant]
US 20150050638A1 · Marquette · 2015 [cited by applicant]
US 20150330385A1 · Lofstrom et al. · 2015 [cited by applicant]
US 20160041082A1 · Van Den Engh · 2016 [cited by applicant]
US 20160266131A1 · Liang · 2016 [cited by examiner]
US 20170299493A1 · Norton · 2017 [cited by applicant]
US 20200190253A1 · Easwaran et al. · 2020 [cited by applicant]
US 20200392346A1 · Bartholomew · 2020 [cited by examiner]
US 20210253864A1 · Matray · 2021 [cited by examiner]
US 20230314418A1 · Moureau · 2023 [cited by examiner]
CN 113383043 · 2021 [cited by applicant]
EP 0672458A2 · 1995 [cited by applicant]
JP 4500008A · 1992 [cited by applicant]
JP 2000516345A · 2000 [cited by applicant]
JP 2015512955A · 2015 [cited by applicant]
WO WO9004019A1 · 1990 [cited by applicant]
WO WO9926067A1 · 1999 [cited by applicant]
WO WO2010033140A2 · 2010 [cited by applicant]
WO WO2013119924A1 · 2013 [cited by applicant]
Bioconjuagate Chem. 2016, vol. 27, No. 5, pp. 1525-1531. [cited by examiner]
Xia, et al. “Influence of Nanostructure on the Exciton Dynamics of Multichromophore Donor-Acceptor Block Copolymers”, ACS Nano May 23, 2017; 11(5):4593-4598. [cited by applicant]
Jayasinghe et al. “Sterile and Disposable Fluidic Subsystem Suitable for Clinical High Speed Fluorescence-Activated Cell Sorting”, Cytometry Part B (Clinical Cytometry) 708:344-354 (2006). [cited by applicant]
Miltenyi Biotec GMBH, CliniMACS® Cell Separation Systems, Product Catalog 2008, 48 pages. [cited by applicant]
Miltenyi Biotec GMBH, CliniMACS® User Manual, US Edition, Software 2.40, Jan. 2014, 128 pages. [cited by applicant]
Miltenyi Biotec GMBH, CliniMACS® User Manual for the CliniMACS® CD34 Reagent System, Jan. 2014, 102 pages. [cited by applicant]
Sandin et al. “Magnetophoresis and cytometry with magnetic microparticles”, International Congress Series, Jun. 2007, vol. 1300, pp. 271-274. [cited by applicant]
Yang et al. “Micro flow cytometry utilizing a magnetic bead-based immunoassay for rapid virus detection”, Biosensors and Bioelectronics, Dec. 1, 2008, vol. 24, No. 4, pp. 855-862. [cited by applicant]
Naganbabu, et al., “Multiexcitation Fluorogenic Labeling of Surface, Intracellular, and Total Protein Pools in Living Cells”, Bioconjugate Chem., 2016, vol. 27, No. 5, pp. 1525-1531. [cited by applicant]
Kesavan, et al, “Carbazole substituted boron dipyrromethenes”, Dalton Transaction, vol. 43, No. 32, 2014, pp. 12405-12413. [cited by applicant]